Yonhap Infomax NewsFeb 6
SK Biopharmaceuticals posted a 13.8% rise in Q4 operating profit to 46.2 billion won, driven by strong Xcopri sales and expanding its R&D pipeline for future growth.
#YonhapInfomax #SKBiopharmaceuticals #Xcopri #OperatingProfit #PrescriptionGrowth #RDPipeline #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=104259
SK Biopharmaceuticals Reports Q4 Operating Profit of 46.2 Billion Won, Up 13.8% – Driven by Strong Xcopri Sales (Comprehensive)

SK Biopharmaceuticals posted a 13.8% rise in Q4 operating profit to 46.2 billion won, driven by strong Xcopri sales and expanding its R&D pipeline for future growth.

Yonhap Infomax
Yonhap Infomax NewsNov 6
Samyang Group Chairman Kim Yoon highlighted the company's 101st anniversary as a pivotal moment, stressing the need for a strong R&D pipeline and embracing AI, while the group recognized innovative projects in biodegradable fillers and hangover relief products at its annual R&D fair.
#YonhapInfomax #SamyangGroup #KimYoon #RDPipeline #BiodegradableFiller #AIInnovation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89494